153 related articles for article (PubMed ID: 24243608)
1. Synthetic chalcone derivatives as inhibitors of cathepsins K and B, and their cytotoxic evaluation.
Ramalho SD; Bernades A; Demetrius G; Noda-Perez C; Vieira PC; Dos Santos CY; da Silva JA; de Moraes MO; Mousinho KC
Chem Biodivers; 2013 Nov; 10(11):1999-2006. PubMed ID: 24243608
[TBL] [Abstract][Full Text] [Related]
2. Chalcones, inhibitors for topoisomerase I and cathepsin B and L, as potential anti-cancer agents.
Kim SH; Lee E; Baek KH; Kwon HB; Woo H; Lee ES; Kwon Y; Na Y
Bioorg Med Chem Lett; 2013 Jun; 23(11):3320-4. PubMed ID: 23608763
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of the cathepsin cysteine proteases B and K by square-planar cycloaurated gold(III) compounds and investigation of their anti-cancer activity.
Zhu Y; Cameron BR; Mosi R; Anastassov V; Cox J; Qin L; Santucci Z; Metz M; Skerlj RT; Fricker SP
J Inorg Biochem; 2011 May; 105(5):754-62. PubMed ID: 21481817
[TBL] [Abstract][Full Text] [Related]
4. Structural factors affecting cytotoxic activity of (E)-1-(Benzo[d ][1,3]oxathiol-6-yl)-3-phenylprop-2-en-1-one derivatives.
Konieczny MT; Bułakowska A; Polak J; Pirska D; Konieczny W; Gryń P; Skladanowski A; Sabisz M; Lemke K; Pieczykolan A; Gałązka M; Wiciejowska K; Wietrzyk J
Chem Biol Drug Des; 2014 Jul; 84(1):86-91. PubMed ID: 24476543
[TBL] [Abstract][Full Text] [Related]
5. Anti-breast cancer activity of heteroaryl chalcone derivatives.
Solomon VR; Lee H
Biomed Pharmacother; 2012 Apr; 66(3):213-20. PubMed ID: 22440895
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and cytotoxicity of 2,5-dihydroxychalcones and related compounds.
Nam NH; Hong DH; You YJ; Kim Y; Bang SC; Kim HM; Ahn BZ
Arch Pharm Res; 2004 Jun; 27(6):581-8. PubMed ID: 15283456
[TBL] [Abstract][Full Text] [Related]
7. Bis-chalcone analogues as potent NO production inhibitors and as cytotoxic agents.
Vijaya Bhaskar Reddy M; Shen YC; Ohkoshi E; Bastow KF; Qian K; Lee KH; Wu TS
Eur J Med Chem; 2012 Jan; 47(1):97-103. PubMed ID: 22115618
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and evaluation of modified chalcone based p53 stabilizing agents.
Iftikhar S; Khan S; Bilal A; Manzoor S; Abdullah M; Emwas AH; Sioud S; Gao X; Chotana GA; Faisal A; Saleem RSZ
Bioorg Med Chem Lett; 2017 Sep; 27(17):4101-4106. PubMed ID: 28743509
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and biological evaluation of novel synthetic chalcone derivatives as anti-tumor agents targeting Cat L and Cat K.
Wang Y; Xue S; Li R; Zheng Z; Yi H; Li Z
Bioorg Med Chem; 2018 Jan; 26(1):8-16. PubMed ID: 29223717
[TBL] [Abstract][Full Text] [Related]
10. In vitro antimalarial activity of chalcones and their derivatives.
Li R; Kenyon GL; Cohen FE; Chen X; Gong B; Dominguez JN; Davidson E; Kurzban G; Miller RE; Nuzum EO
J Med Chem; 1995 Dec; 38(26):5031-7. PubMed ID: 8544179
[TBL] [Abstract][Full Text] [Related]
11. Cytotoxic activity evaluation and QSAR study of chromene-based chalcones.
Firoozpour L; Edraki N; Nakhjiri M; Emami S; Safavi M; Ardestani SK; Khoshneviszadeh M; Shafiee A; Foroumadi A
Arch Pharm Res; 2012 Dec; 35(12):2117-25. PubMed ID: 23263805
[TBL] [Abstract][Full Text] [Related]
12. Synthesis of proline analogues as potent and selective cathepsin S inhibitors.
Kim M; Jeon J; Song J; Suh KH; Kim YH; Min KH; Lee KO
Bioorg Med Chem Lett; 2013 Jun; 23(11):3140-4. PubMed ID: 23639544
[TBL] [Abstract][Full Text] [Related]
13. Neuroprotective effect of synthetic chalcone derivatives as competitive dual inhibitors against μ-calpain and cathepsin B through the downregulation of tau phosphorylation and insoluble Aβ peptide formation.
Jeon KH; Lee E; Jun KY; Eom JE; Kwak SY; Na Y; Kwon Y
Eur J Med Chem; 2016 Oct; 121():433-444. PubMed ID: 27318120
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and anti-cancer activity evaluation of novel prenylated and geranylated chalcone natural products and their analogs.
Wang HM; Zhang L; Liu J; Yang ZL; Zhao HY; Yang Y; Shen D; Lu K; Fan ZC; Yao QW; Zhang YM; Teng YO; Peng Y
Eur J Med Chem; 2015 Mar; 92():439-48. PubMed ID: 25590864
[TBL] [Abstract][Full Text] [Related]
15. SAR studies of differently functionalized chalcones based hydrazones and their cyclized derivatives as inhibitors of mammalian cathepsin B and cathepsin H.
Raghav N; Singh M
Bioorg Med Chem; 2014 Aug; 22(15):4233-45. PubMed ID: 24913985
[TBL] [Abstract][Full Text] [Related]
16. Design and synthesis of naphthylchalcones as novel anti-leukaemia agents.
Leitão EPT; Ascenso OS; Santos de Almeida T; González I; Hernández I; Quintana J; Estévez F; Rijo P
Bioorg Chem; 2021 Dec; 117():105348. PubMed ID: 34736139
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and anticancer activity of nitric oxide donating/chalcone hybrids.
Mourad MA; Abdel-Aziz M; Abuo-Rahma Gel-D; Farag HH
Eur J Med Chem; 2012 Aug; 54():907-13. PubMed ID: 22703846
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, and biological evaluation of Mannich bases of heterocyclic chalcone analogs as cytotoxic agents.
Reddy MV; Su CR; Chiou WF; Liu YN; Chen RY; Bastow KF; Lee KH; Wu TS
Bioorg Med Chem; 2008 Aug; 16(15):7358-70. PubMed ID: 18602831
[TBL] [Abstract][Full Text] [Related]
19. DNA-binding affinity and anticancer activity of β-carboline-chalcone conjugates as potential DNA intercalators: Molecular modelling and synthesis.
Shankaraiah N; Siraj KP; Nekkanti S; Srinivasulu V; Sharma P; Senwar KR; Sathish M; Vishnuvardhan MV; Ramakrishna S; Jadala C; Nagesh N; Kamal A
Bioorg Chem; 2015 Apr; 59():130-9. PubMed ID: 25771335
[TBL] [Abstract][Full Text] [Related]
20. Synthesis of chalcone derivatives on steroidal framework and their anticancer activities.
Saxena HO; Faridi U; Kumar JK; Luqman S; Darokar MP; Shanker K; Chanotiya CS; Gupta MM; Negi AS
Steroids; 2007 Nov; 72(13):892-900. PubMed ID: 17850837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
